Takara Bio Inc., a subsidiary of Takara Holdings Inc., is a Japan‐based biotechnology company specializing in the development, manufacture and distribution of research reagents, instruments and cell and gene therapy solutions. With its headquarters in Kusatsu, Shiga, the company leverages decades of expertise in molecular biology and enzymology to serve academic institutions, pharmaceutical and biotech firms, diagnostic laboratories and contract research organizations worldwide.
The company’s product portfolio encompasses molecular biology reagents such as DNA polymerases, reverse transcriptases, cloning and library‐preparation kits for next‐generation sequencing, and real‐time PCR systems. In the cell and gene therapy arena, Takara Bio offers viral vector platforms—adenoviral, lentiviral and AAV systems—for gene delivery, as well as cell culture media and transfection reagents designed to support CAR‐T, stem cell and regenerative medicine research. Complementing these off‐the‐shelf products, the company provides contract development and manufacturing organization (CDMO) services for clinical‐grade viral vectors, helping partners advance gene therapy candidates from process development through commercial supply.
Founded in the early 2000s as a spin‐off from Takara Shuzo’s biotechnology division, Takara Bio has expanded its footprint through strategic acquisitions—most notably the purchase of U.S.‐based Clontech Laboratories—and the establishment of subsidiaries in North America, Europe and Asia. This global network enables the company to support customers across key research hubs in the Americas, EMEA and the Asia-Pacific region. Takara Bio’s sustained investment in R&D and manufacturing capacity underpins its role as a full-service provider in both basic life-science research and the emerging cell and gene therapy market.
AI Generated. May Contain Errors.
Free TKBIF Stock Alerts